Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR)

Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR)

Rociletinib (CO-1686), a 2,4-diaminopyrimidine derivative, is a highly potent tyrosine kinase inhibitor (TKI) that acts on epidermal growth factor receptor (EGFR) with L858R/T790M mutations. We supposed radioiodinated CO-1686 would function as a useful tool for monitoring EGFR L858R/T790M mutations....

Full description

Bibliographic Details
Main Authors: Muammar Fawwaz, Kenji Mishiro, Ryuichi Nishii, Izumi Sawazaki, Kazuhiro Shiba, Seigo Kinuya, Kazuma Ogawa
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Molecules
Subjects:
imaging
EGFR
prediction of therapeutic effects
mutation status
radiopharmaceutical
tyrosine kinase inhibitor
Online Access:https://www.mdpi.com/1420-3049/25/12/2914

Internet

https://www.mdpi.com/1420-3049/25/12/2914

Similar Items